术前[18F]-FDG摄取作为BRAF靶向治疗后残留间变性及低分化甲状腺癌的标志物
本回顾性单中心研究纳入30例接受至少30天新辅助BRAF靶向治疗及免疫治疗后手术的BRAF V600E突变间变性甲状腺癌患者,术前30天内行FDG-PET/CT,共分析94个手术切除头颈部病灶。高风险病理(间变性甲状腺癌、低分化甲状腺癌)病灶的SULmax中位数5.01显著高于低风险病理(甲状腺乳头状癌、阴性)的1.29(P<.001);以SULmax≥2.75为阈值检测高风险病理的敏感度0.784、特异度0.702、准确度0.734;至少1个高风险病灶者总生存较差(中位259天 vs 未达到,P=.038)。
要点
- BRAF突变间变性甲状腺癌新辅助靶向治疗后,术前FDG-PET以SULmax≥2.75提示残留高风险病理(间变性/低分化甲状腺癌)。
- 高风险病灶SULmax中位数5.01(IQR 2.81-10.95)高于低风险病灶1.29(IQR 1.06-3.1)(P<.001)。
- 阈值SULmax≥2.75检测高风险病理的敏感度0.784、特异度0.702、准确度0.734。
核心结论
- 术前FDG-PET可无创识别BRAF突变间变性甲状腺癌新辅助BRAF靶向治疗及免疫治疗后残留的高风险病理,FDG高摄取可能作为与残留高风险病理相关的早期预后标志物。
研究设计与样本
- 回顾性单中心研究,纳入30例接受至少30天新辅助BRAF靶向治疗且术前30天内行FDG-PET/CT的BRAF V600E突变间变性甲状腺癌连续患者,共94个手术切除头颈部病灶,以手术病理最高分级为参考标准。
关键影像表现/征象
- 高风险病理病灶的FDG摄取高于低风险病理病灶:SULmax中位数5.01(IQR 2.81-10.95)vs 1.29(IQR 1.06-3.1)(P<.001,Mann-Whitney U检验)。
- 94个病灶中57个(60.6%)为低风险(39个阴性、18个甲状腺乳头状癌),37个(39.4%)为高风险(29个间变性甲状腺癌、8个低分化甲状腺癌)。
诊断标准与关键数值
- 以SULmax≥2.75为最佳阈值检测高风险病理(间变性甲状腺癌、低分化甲状腺癌)的敏感度0.784(95%CI 0.628-0.886)、特异度0.702(95%CI 0.573-0.805)、准确度0.734(95%CI 0.637-0.813)。
- 按上述阈值,至少1个高风险病灶患者的中位总生存为259天,无高风险病灶患者未达到(P=.038,log-rank检验)。
临床应用与阅片要点
- 对BRAF突变间变性甲状腺癌新辅助靶向治疗后的术前FDG-PET/CT,可测量头颈部病灶SULmax并以≥2.75评估残留高风险病理可能。
- 阅片时需对每个头颈部病灶逐一测量SULmax并与手术病理最高分级对应,避免遗漏低分化或间变性成分。
局限性
- 原文为回顾性、单中心研究,样本量为30例患者、94个病灶。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Neoadjuvant BRAF-directed therapy and immunotherapy followed by surgery improves survival in patients with BRAF V600E-mutant anaplastic thyroid carcinoma (ATC), more so in those who have complete ATC pathologic response. This study assesses the ability of FDG-PET to noninvasively detect residual high-risk pathologies including ATC and poorly differentiated thyroid carcinoma (PDTC) in the preoperative setting.
MATERIALS AND METHODS: This retrospective, single-center study included consecutive BRAF V600E-mutant patients with ATC treated with at least 30 days of neoadjuvant BRAF-directed therapy and who underwent FDG-PET/CT within 30 days before surgery. The highest pathologic grade observed for every head and neck lesion resected was recorded. Each lesion on preoperative PET/CT was retrospectively characterized. The primary end point was to contrast the standardized uptake normalized by lean body mass (SULmax) for lesions with residual high-risk (ATC, PDTC) versus low-risk pathologies (papillary thyroid carcinoma, negative). An optimal SULmax threshold was then identified by using a receiver operating characteristic analysis, and the ability of this threshold to noninvasively and preoperatively risk-stratify patients by overall survival was then evaluated with a Kaplan-Meier plot.
RESULTS: Thirty patients (mean age 66.5 ± 9.0; 17 men) were included in this study, with 94 surgically sampled lesions. Of these lesions, 57 (60.6%) were low-risk (39 negative, 18 papillary thyroid carcinoma) and 37 (39.4%) were high-risk (29 ATC, 8 PDTC). FDG uptake was higher for high-risk compared with low-risk pathologies: median SULmax 5.01 (interquartile range [IQR] 2.81-10.95) versus 1.29 (IQR 1.06-3.1) (P < .001, Mann-Whitney U test). The sensitivity, specificity, and accuracy for detecting high-risk pathologies at the optimal threshold of SULmax ≥2.75 were 0.784 [95% CI, 0.628-0.886], 0.702 [95% CI, 0.573-0.805], and 0.734 [95% CI, 0.637-0.813], respectively. Patients with at least 1 high-risk lesion identified with the aforementioned cutoff had a worse prognosis compared with patients without high-risk lesions in the head and neck: median overall survival for the former group was 259 days and was not attained for the latter (P = .038, log-rank test).
CONCLUSIONS: Preoperative FDG-PET noninvasively identifies lesions with residual high-risk pathologies following neoadjuvant BRAF-directed targeted therapy and immunotherapy for BRAF-mutated ATC. FDG-PET avidity may serve as an early prognostic marker that correlates with residual high-risk pathology in BRAF-mutated ATC after neoadjuvant therapy.
引用
- Dagher SA, Learned KO, Dagher R, et al. [18F]-FDG Uptake as a Marker of Residual Anaplastic and Poorly Differentiated Thyroid Carcinoma following BRAF-Targeted Therapy. AJNR Am J Neuroradiol. 2025. PMID: 39572200. doi:10.3174/ajnr.A8588
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。